PGNY Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 3.64% compared to Progyny's net margin of 16.64%. Progyny's return on equity of 11.31% beat Delcath Systems's return on equity of -251.36%.

Progyny has a consensus price target of $30.22, signalling upside risk potential of 31.5%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 93.94%. Given that Delcath Systems has higher upside potential than Progyny, analysts believe Delcath Systems is more attractive than Progyny.

Progyny has a beta of 1.350, which suggesting that the stock is 34.952% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $286.6M, which are larger than Delcath Systems quarterly revenues of $11.2M. Progyny's net income of $10.4M is higher than Delcath Systems's net income of $1.9M. Notably, Progyny's price-to-earnings ratio is 24.72x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.24x versus 13.18x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 3.64% compared to Progyny's net margin of -5.4%. Progyny's return on equity of 11.31% beat Exact Sciences's return on equity of -6.77%.

Progyny has a consensus price target of $30.22, signalling upside risk potential of 31.5%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 21.05%. Given that Progyny has higher upside potential than Exact Sciences, analysts believe Progyny is more attractive than Exact Sciences.

Progyny has a beta of 1.350, which suggesting that the stock is 34.952% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $286.6M, which are smaller than Exact Sciences quarterly revenues of $708.7M. Progyny's net income of $10.4M is higher than Exact Sciences's net income of -$38.2M. Notably, Progyny's price-to-earnings ratio is 24.72x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.24x versus 4.04x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of 3.64% compared to Progyny's net margin of -7.18%. Progyny's return on equity of 11.31% beat Natera's return on equity of -26.45%.

Progyny has a consensus price target of $30.22, signalling upside risk potential of 31.5%. On the other hand Natera has an analysts' consensus of $167.90 which suggests that it could grow by 3.54%. Given that Progyny has higher upside potential than Natera, analysts believe Progyny is more attractive than Natera.

Progyny has a beta of 1.350, which suggesting that the stock is 34.952% more volatile than S&P 500. In comparison Natera has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.789%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $286.6M, which are smaller than Natera quarterly revenues of $439.8M. Progyny's net income of $10.4M is higher than Natera's net income of -$31.6M. Notably, Progyny's price-to-earnings ratio is 24.72x while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.24x versus 12.88x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of 3.64% compared to Progyny's net margin of -14.42%. Progyny's return on equity of 11.31% beat Star Equity Holdings's return on equity of -10.13%.

Progyny has a consensus price target of $30.22, signalling upside risk potential of 31.5%. On the other hand Star Equity Holdings has an analysts' consensus of -- which suggests that it could grow by 380.77%. Given that Star Equity Holdings has higher upside potential than Progyny, analysts believe Star Equity Holdings is more attractive than Progyny.

Progyny has a beta of 1.350, which suggesting that the stock is 34.952% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.080, suggesting its less volatile than the S&P 500 by 91.951%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Star Equity Holdings pays out 7.62% of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Progyny quarterly revenues are $286.6M, which are larger than Star Equity Holdings quarterly revenues of $13.7M. Progyny's net income of $10.4M is higher than Star Equity Holdings's net income of -$2M. Notably, Progyny's price-to-earnings ratio is 24.72x while Star Equity Holdings's PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.24x versus 0.13x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.